5.38
-0.005(-0.09%)
Currency In USD
Address
300 Technology Square
Cambridge, MA 02139
United States of America
Phone
617-915-6680
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
September 14, 2022
| Name | Title | Pay | Year Born |
| Natalie C. Holles | Chief Executive Officer & Director | 930,248 | 1973 |
| Julie Person | Chief Administrative Officer | 574,000 | 1974 |
| Edward R. Conner | Chief Medical Officer | 672,000 | 1973 |
| Christopher Murphy | Chief Financial & Business Officer | 673,029 | 1984 |
| Christopher J. Dinsmore | Chief Scientific Officer | 0 | 1967 |
| Dennis Dean | Chief Non-Clinical Development Officer | 0 | 1962 |
| Steven Sweeney | Senior Vice President of Development Operations | 0 | N/A |
| Jennifer Dittman | Chief Operating Officer | 0 | 1982 |
| Ommer Chohan | Treasurer & Secretary | 0 | N/A |
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
